focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7.375
Bid: 7.25
Ask: 7.50
Change: 0.075 (1.03%)
Spread: 0.25 (3.448%)
Open: 7.30
High: 7.375
Low: 7.30
Prev. Close: 7.30
IXI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

5 Jan 2010 09:10

RNS Number : 0217F
Phytopharm PLC
05 January 2010
 

TR-1: notification of major interests in shares 

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

Phytopharm plc

2. Reason for the notification   (please tick the appropriate box or boxes)

An acquisition or disposal of voting rights 

An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An event changing the breakdown of voting rights

Other (please specify): Placing and a change in the ISC

X

3. Full name of person(s) subject to the notification obligation:

Gartmore Investment Limited

4. Full name of shareholder(s) (if different from 3.):

See 9

5. Date of the transaction (and date on which the threshold is crossed or reached if different)

31 December 2009

6. Date on which issuer notified:

4 January 2010

7. Threshold(s) that is/are crossed or reached:

7%

8. Notified details:

A: Voting rights attached to shares

Class/type of shares 

 if possible using the ISIN CODE

Situation previous to the Triggering transaction 

Resulting situation after the triggering transaction

Number of Shares 

Number of Voting Rights 

Number of shares 

Number of voting rights 

% of voting rights

Direct

Direct x

Indirect xi

Direct

Indirect

Ordinary 1 Pence

GB0006869720

10,530,299

10,530,299

23,348,755

Nil

25,348,755

Nil

7.312%

B: Financial Instruments

Resulting situation after the triggering transaction 

Type of financial instrument 

Expiration date 

Exercise/ Conversion Period/ Date 

Number of voting rights that may be acquired if the instrument is exercised/ converted. 

% of voting rights

Total (A+B)

Number of voting rights

% of voting rights

25,348,755

7.312%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:

Name of the Company/Fund

Number of Shares

% of issued share capital

Gartmore Fund Managers Ltd A/C Gartmore UK & Irish Smaller Companies 

2,106,746

0.608%

Gartmore Investment Limited - Gartmore Fledgling Trust plc

21,376,704

6.166%

Gartmore Investment Limited - Strathclyde Pension Fund

1,865,305

0.538%

Total direct

Nil

Nil

Total Indirect

25,348,755

7.312%

Total

25,348,755

7.312%

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to hold voting rights:

13. Additional information:

Notification using the total voting rights figure of 346,677,433

14. Contact name:

Zoe McGowan, Company Secretary

15. Contact telephone number:

01480 437697

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLKELBBBFFBBBD
Date   Source Headline
23rd Dec 20197:00 amRNSIXICO announces updates to client contracts
20th Dec 20197:00 amRNSStatement re Annual Report and Notice of AGM
9th Dec 20199:26 amRNSPDMR share sale
9th Dec 20197:02 amRNSHolding(s) in Company
9th Dec 20197:00 amRNSPDMR share purchase
5th Dec 20198:22 amRNSDirector/PDMR Shareholding
4th Dec 20197:00 amRNSFinancial Results for the year ended 30 Sept 2019
2nd Dec 20197:00 amRNSIXICO to Present at Alzheimer's Disease Congress
22nd Nov 20197:00 amRNSNotice of Results
5th Nov 20199:00 amRNSIXICO to Present at HD and Ataxia Conferences
4th Nov 20192:51 pmRNSHolding(s) in Company
30th Oct 20199:00 amRNSIXICO to Present at 10th Annual CNS Summit 2019
28th Oct 20197:00 amRNSIXICO announces client contracts and appointed CBO
18th Oct 20197:00 amRNSHolding(s) in Company
15th Oct 20197:00 amRNSTrading Update for year ended 30 September 2019
11th Sep 20197:00 amRNSDirector/PDMR Shareholding
9th Sep 201911:48 amRNSHolding(s) in Company
9th Sep 201911:46 amRNSHolding(s) in Company
5th Sep 20193:43 pmRNSHolding(s) in Company
4th Sep 20195:07 pmRNSHolding(s) in Company
28th Aug 201912:21 pmRNSIssue of Equity
22nd Aug 20197:00 amRNSDirectorate Change
20th Aug 20195:38 pmRNSDirector/PDMR Shareholding
19th Aug 20194:40 pmRNSSecond Price Monitoring Extn
19th Aug 20194:35 pmRNSPrice Monitoring Extension
19th Aug 20197:00 amRNSTrading Update
9th Aug 20197:00 amRNSIXICO provides update on new & current contracts
23rd Jul 201911:05 amRNSSecond Price Monitoring Extn
23rd Jul 201911:00 amRNSPrice Monitoring Extension
11th Jul 20197:00 amRNSDirector and PDMR share purchase
10th Jun 20197:00 amRNSHolding(s) in Company
31st May 20197:00 amRNSHolding(s) in Company
31st May 20197:00 amRNSHolding(s) in Company
31st May 20197:00 amRNSHolding(s) in Company
31st May 20197:00 amRNSHolding(s) in Company
31st May 20197:00 amRNSHolding(s) in Company
22nd May 20197:00 amRNSHalf Yearly Report to 31 March 2019
10th May 20197:00 amRNSNotice of Results
25th Apr 20197:00 amRNSUpdate for first half of year ending 31 March 2019
24th Apr 20197:00 amRNSAnnounces two new biopharmaceutical contracts
12th Apr 20197:00 amRNSChange of Adviser
19th Mar 20194:20 pmRNSHolding(s) in Company
18th Mar 201912:24 pmRNSDirector/PDMR Shareholding
13th Mar 20197:00 amRNSDirector/PDMR Shareholding
5th Mar 20197:00 amRNSLate phase clinical study in Huntington's disease
1st Mar 20197:00 amRNSIXICO chosen for new Medical Imaging & AI Centre
7th Feb 20197:00 amRNSAppointment of Chief Financial Officer
11th Dec 20187:00 amRNSDirectorate Change
4th Dec 20187:00 amRNSFinal Results
4th Dec 20187:00 amRNSScope expanded with top 10 biopharma company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.